Rheumatology Book


Interleukin-6 Receptor Antagonist

Aka: Interleukin-6 Receptor Antagonist, Anti-IL6 monoclonal antibody, Tocilizumab, Actemra, Sarilumab, Kevzara, Siltuximab, Sylvant
  1. Mechanism
    1. Blockade of of IL-6 decreases production of proinflammatory Cytokines and acute phase reactants
  2. Indications
    1. Severe Cytokine Release Syndrome (CRS)
      1. CAR T-Cell Therapy Related CRS (FDA approved use of Tocilizumab)
      2. COVID-19 related CRS (experimental Tocilizumab use in 2020)
    2. Multicentric Castleman’s disease (Siltuximab)
    3. Rheumatologic Conditions (Tocilizumab)
      1. Rheumatoid Arthritis
      2. Giant Cell Arteritis
      3. Polyarticular Juvenile Idiopathic Arthritis
      4. Systemic Juvenile Idiopathic Arthritis
  3. Preparations
    1. Tocilizumab
      1. IL-6 receptor Antagonist (Monoclonal Antibody)
      2. Cytokine Release Syndrome Dosing: 8 mg/kg (up to 800 mg) or for <30 kg, use 12 mg/kg
    2. Sarilumab (Kevzara)
    3. Siltuximab (Sylvant)
      1. Binds IL-6 (Monoclonal Antibody)
  4. Adverse Effects
    1. Severe infections (esp. opportunistic Viral Infections, Bacterial Infections, invasive fungal infections)
    2. Reactivated Herpes Zoster
    3. Reactivated Tuberculosis
    4. Neutropenia
    5. Thrombocytopenia
    6. Increased liver enzymes
    7. Hyperlipidemia
    8. GI perforation
  5. References
    1. Kamer and LoVecchio (2020) Crit Dec Emerg Med 34(8): 24

You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree